Propel Bio Management, LLC T Scan Therapeutics, Inc. Transaction History
Propel Bio Management, LLC
- $82.4 Billion
- Q2 2025
A detailed history of Propel Bio Management, LLC transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Propel Bio Management, LLC holds 2,087,139 shares of TCRX stock, worth $3.49 Million. This represents 3.67% of its overall portfolio holdings.
Number of Shares
2,087,139
Previous 2,087,139
-0.0%
Holding current value
$3.49 Million
Previous $2.88 Billion
5.07%
% of portfolio
3.67%
Previous 3.35%
Shares
1 transactions
Others Institutions Holding TCRX
# of Institutions
80Shares Held
37.8MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR7.86MShares$13.1 Million3.37% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$8.73 Million0.3% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$7.45 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$4.65 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.15MShares$3.59 Million0.0% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $31.6M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...